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A B S T R A C T
Multidrug resistance protein 4 (MRP4, ABCC4) is an efﬂux membrane transporter expressed in renal
tubules, hepatocytes, brain capillaries, prostate and blood cells. MRP4 drives energy dependent efﬂux of
important physiological and pharmacological compounds. MRP4 expression and function is highly
variable but cannot be fully attributed to known mechanisms. The goal of this study was to characterize
ABCC4 regulation by miRNAs and to assess the inﬂuence of ABCC4 30-UTR polymorphisms on ABCC4
regulation by miRNAs. miR-124a and miR-506 decreased MRP4 protein levels in HEK293T/17 cells 20–
30% and MRP4 function by 50%. These miRNAs did not affect ABCC4 mRNA expression. Moreover, miR-
124a and miR-506 expression was negatively correlated with MRP4 protein expression in 26 human
kidney samples (Spearman r = 0.62, P = 0.007 and r = 0.41, P = 0.03 for miR-124a and miR-506,
respectively). To assess the effect of ABCC4 30-UTR polymorphisms, six common 30-UTR haplotypes were
inferred in Caucasians, African Americans and Asians and tested in luciferase reporter assays. Multiple
ABCC4 30-UTR haplotypes caused signiﬁcant reductions in luciferase activity; in the presence of miR-
124a or miR-506 mimics the luciferase activity of all six ABCC4 30-UTR haplotypes was further reduced.
Mutation of the putative binding site for miR-124a and miR-506 in the ABCC4 30-UTR eliminated the
effect of these miRNAs. In conclusion, ABCC4 is directly regulated by miR-124a and miR-506 but
polymorphisms in the ABCC4 30-UTR have no signiﬁcant effect on this miRNA regulation. Regulation of
ABCC4 by miRNAs represents a novel mechanism for regulation of MRP4 function.
 2013 Elsevier Inc. All rights reserved.
Contents lists available at ScienceDirect
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jo u rn al h om epag e: ww w.els evier .c o m/lo cat e/b io c hem p har m1. Introduction
The multidrug resistance protein 4 (MRP4), encoded by ABCC4,
is a member of the ATP-binding cassette (ABC) family of membrane
transporters. MRP4 is expressed in a variety of tissues and can be
localized both apically (renal proximal tubule cells, luminal side of
brain capillary endothelium) and basolaterally (prostate tubuloa-
cinar cells and hepatocytes). It is also detected in epithelial cells of
seminal vesicles, ovary, adrenal gland, dendritic cells, erythrocytes,
monocytes and delta granules of platelets [1,2]. MRP4 plays an
important role in the pharmacokinetics of a wide variety of
endogenous and exogenous compounds. This transporter drives
energy dependent efﬂux of such physiologically relevant com-
pounds as cyclic nucleotides, ADP, prostaglandins, leukotrienes,
taurine and glycine conjugates of bile acids, and glucuronide
conjugates of steroid hormones. It also transports a broad
spectrum of xenobiotics including antiviral drugs (adefovir,Abbreviations: MCB, (monochlorobimane); ABCC4, (ATP-binding cassette trans-
porter member C4); MRP4, (multidrug resistance protein member 4).
* Corresponding author. Tel.: +1 415 476 1159, fax: +1 415 514 4361.
E-mail address: deanna.kroetz@ucsf.edu (D.L. Kroetz).
0006-2952/$ – see front matter  2013 Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.bcp.2013.10.017tenofovir), antibiotics (ceftizoxime, cefmetazole), antihypertensive
drugs (furosemide, hydrochlorothiazide, olmesartan) and antican-
cer agents (methotrexate, 6-thioguanine, 6-mercaptopurine,
topotecan) [2,3]. The importance of MRP4-mediated transport of
endogenous and therapeutic compounds has been clearly demon-
strated in mouse models lacking Mrp4 expression [4–6].
MRP4 expression and function is highly variable. It has been
associated with the onset and prognosis of several diseases [7–9]
as well as drug efﬁcacy and toxicities [10,11]. A number of common
ABCC4 promoter and non-synonymous coding region polymor-
phisms have been associated with MRP4 expression and/or
function [12–14] and with drug disposition, response and adverse
events [15–17]. Currently, ABCC4 regulation cannot be fully
explained or attributed to known ABCC4 polymorphisms [18].
In the present study we focused on ABCC4 regulation by
miRNAs. miRNAs are 18–25 nucleotide long non-coding RNAs
regulating gene expression. They are generated from endogenously
transcribed primary miRNA (pri-miRNA) hairpin structures, which
are further cleaved in the cell nucleus by Drosha (RNase III) [19],
yielding a 70–100 nucleotide long stem loop precursor miRNA
(pre-miRNA). Pre-miRNAs are trafﬁcked from the nucleus to the
cytoplasm by Exportin 5 [20] and are further processed by Dicer
(RNase III) [21] to produce mature miRNA duplexes that are 18–25
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incorporated into a RNA-induced silencing complex (RISC) where
it binds to a complementary sequence of 30-UTR. The ‘‘seed’’, 2–9
nucleotides at the 50 end of miRNA, is crucial for binding to target
mRNA. Upon binding, the miRNA initiates translational repression
or cleavage of targeted mRNA [22,23].
A signiﬁcant number of miRNAs have been discovered and
annotated, although only a small portion have been functionally
validated. miRNAs are currently implicated in the regulation of
metabolic enzymes (CYP3A4 and CYP1B1) [24,25] as well as drug
transporters (ABCB1, ABCB6, ABCC1, ABCC2, ABCC4, ABCC5,
ABCC10, ABCC12 and ABCG2) [26–34] and it is likely that they
are involved in the regulation of drug response. The present study
was designed to characterize ABCC4 regulation by predicted
miRNAs and to assess the inﬂuence of ABCC4 30-UTR genetic
polymorphisms on ABCC4 regulation by miRNAs.
2. Materials and methods
2.1. In silico predictions of miRNAs targeting ABCC4
We used multiple web-based tools designed to predict miRNA
targets, namely miRBase (http://www.mirbase.org/), PicTar (http://
pictar.mdc-berlin.de/), Segal Lab tool (http://genie.weizmann.ac.il/
pubs/mir07/index.html), miRDB (http://mirdb.org/miRDB/), miR-
NAMap (http://mirnamap.mbc.nctu.edu.tw/), miRacle (http://mir-
acle.igib.res.in/miracle/), miRTar (http://mirtar.mbc.nctu.edu.tw/
human/), and DIANA Lab (http://diana.cslab.ece.ntua.gr/). All of
these tools take into account complementarity of the miRNA ‘‘seed’’,
miRNA binding site conservation, and energy of binding to miRNA.
The Segal Lab tool miRNA prediction algorithm also considers the
energy of mRNA unwinding, thus accounting for mRNA secondary
structure. miRNAs predicted by at least two independent tools were
selected for further testing.
2.2. Reagents and miRNA mimics
All miRNA mimics and ABCC4 siRNA were purchased from
Applied Biosystems (Foster City, CA, USA). Monochlorobimane
(MCB) was purchased from Sigma-Aldrich (St. Louis, MO, USA).
2.3. Human kidney samples
Twenty six healthy human kidney samples were purchased
from Capital Biosciences, Gaithersburg, MD, USA.
2.4. Cell culture
Human embryonic kidney (HEK293T/17) cells (from American
Tissue Culture Collection, ATCC, Manassas, VA, USA) were cultured
in complete DMEM supplemented with 10% FBS at 37 8C in a
humidiﬁed atmosphere containing 5% CO2.
2.5. Transfection of mimic miRNAs into HEK293T/17 cells
HEK293T/17 cells were seeded in 24 well plates at a density of
1  105 cells/well, allowed to attach and then transfected with 5, 20,
50 or 100 nM of miRNA mimics. All transfections were performed
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according
to the manufacturer’s protocol. Seventy two hours post transfection
cells were washed with PBS and lysed on ice for 10 min with CelLytic
reagent (Sigma-Aldrich, St. Louis, MO, USA). Cell lysates were then
centrifuged at 4 8C at 10,000g for 10 min and the supernatant was
collected. Protein concentrations were measured using a BCA assay
(Thermo Scientiﬁc, Rockford, IL, USA) and samples were frozen at
80 8C until MRP4 protein detection.2.6. Protein isolation and Western blot analysis
Proteins were isolated using mirVANATMPARISTM kit (Ambion
by Life Technologies, Foster City, CA, USA) according to the
manufacturer’s protocol. Proteins (30 mg/lane) were separated on
4–15% Tris–HCL Criterion gels (Bio-Rad, Hercules, CA, USA) by SDS-
PAGE at 80 V and then transferred onto nitrocellulose membranes
at 250 mA for 2 h. Membranes were blocked in 2% skim milk for 1 h
at room temperature and incubated overnight at 4 8C with anti-
MRP4 antibody (M4I-10) at 1:250 dilution (Alexis Biochemicals,
San Diego, CA, USA) or anti-GAPDH antibody (ab9483) at 1:100,000
dilution (Abcam, Cambridge, MA, USA). The following day,
membranes were washed three times with PBS and then incubated
with IRdye 800CW goat anti-rat (anti-MRP4) or anti-mouse (anti-
GAPDH) ﬂuorescent secondary antibody (LI-COR, Lincoln, NE, USA)
at 1:10,000 dilution. Membranes were washed with PBS and
visualized on an Odyssey1 Sa Infrared Imaging System (LI-COR,
Lincoln, NE, USA).
2.7. RNA isolation and real time quantitative RT-PCR (qRT-PCR)
analysis
Total RNA enriched in small RNAs was isolated using mirVA-
NATMPARISTMkit (Ambion by Life Technologies, Foster City, CA, USA)
according to the manufacturer’s protocol. To obtain cDNA for ABCC4
and GUSB measurements, 500 ng of total RNA were reverse
transcribed in a 10 mL reaction using the SuperScript III Reverse
Transcriptase kit (Invitrogen, Carlsbad, CA) according to the
manufacturer’s protocol. To obtain cDNA for microRNA measure-
ments, 20 ng of total RNA were reverse transcribed in a 20 mL
reaction using TaqMan1 MicroRNA Reverse Transcription Kit
(Applied Biosystems, Foster City, CA, USA) according to the
manufacturer’s multiplex protocol with slight modiﬁcations.
Speciﬁcally, each reaction contained 2 mL of each original 5X RT
primer set (Applied Biosystems, Foster City, CA, USA; assay ID
numbers: 001182, 001050, 001093, 001006 for miR-124a, miR-506,
RNU6B and RNU48, respectively), 0.4 mL of 100 mM dNTPs, 2 mL of
reverse transcriptase (50 U/mL), 2 mL of 10X RT buffer, 0.25 mL of
RNase inhibitor (20 U/mL) and water up to 20 mL. ABCC4, GUSB and
microRNA PCR reactions contained 1 mL of cDNA, 5 mL of 2X
SensiFASTTM HiROX mix (Bioline Reagents Ltd., Boston, MA, USA)
and 0.5 mL of one of the primer/probe mixes (Applied Biosystems,
Foster City, CA, USA; assay ID numbers Hs00195260_m1,
Hs99999908_m1, 001182, 001050, 001093, 001006 for ABCC4,
GUSB, miR-124a, miR-506, RNU6B and RNU48, respectively). Real
time quantitative PCR measurements were performed on a HT7900
Real Time Fast PCR System (Applied Biosystems, Foster City, CA,
USA). ABCC4 mRNA expression was expressed relative to GAPDH
mRNA expression, miR-124a and miR-506 levels were expressed
relative to geometric mean of RNU6B and RNU48 RNA expression
using the 2DDCt method [35].
2.8. MRP4 transport assay
Seventy two hours after transfection with negative miRNA,
siRNA, miR-124a and miR-506 as described above the efﬂux of
bimane-glutathione, a metabolite of monochlorobimane (MCB)
and a MRP4 substrate, was measured with slight modiﬁcations
as previously described [36]. Brieﬂy, the cells were washed with
warm PBS and then incubated with 100 mM MCB in DMEM at
10 8C for 60 min. The plate was placed on ice and after washing
with cold Hank’s balanced salt solution (HBSS) the cells were
incubated at 37 8C in HBSS containing 5.6 mM glucose for
15 min. Incubation buffer was collected for bimane-glutathione
measurements. The ﬂuorescence of collected samples was read
using an excitation wavelength of 385 nm and an emission
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nedorf, Switzerland). The cells were washed with PBS and lysed
on ice for 10 min with CelLytic reagent (Sigma-Aldrich, St. Louis,
MO, USA). Cell lysates were then centrifuged at 4 8C at 10,000g
for 10 min and supernatant was collected. Protein concentra-
tions were measured using a BCA assay (Thermo Scientiﬁc,
Rockford, IL, USA). Data was processed as relative ﬂuorescence
units corrected for total protein and presented as percent of
microRNA negative control.
2.9. Construction and mutagenesis of ABCC4 30-UTR haplotypes in
luciferase reporter plasmids
The 30-UTR of ABCC4 was ampliﬁed from human liver cDNA and
was inserted downstream of the luciferase gene in the pGL3
promoter plasmid (Promega Corporation, Madison, WI, USA). Site-
directed mutagenesis to obtain ABCC4 30-UTR haplotypes was
performed using a Quick-Change site-directed mutagenesis kit
(Stratagene, La Jolla, CA, USA) according to the manufacturer’s
protocol.
2.10. Luciferase assays
HEK293T/17 cells were seeded on 96 well plates at a density of
5  104 cells/well. The pGL3 promoter empty vector or plasmids
containing ABCC4 30-UTR reference and variant haplotypes were
co-transfected with negative miRNA, siRNA, miR-124a or miR-506
together with Renilla luciferase vector into HEK293T/17 cells using
the Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA).
Renilla luciferase vector served as a transfection efﬁciency control.
Cells were incubated for 24 h at 37 8C in humidiﬁed atmosphere
with 5% CO2, after which they were washed with phosphate
buffered saline and incubated with 80 mL of passive lysis buffer
(Promega, Madison, WI) at room temperature on a shaker for
30 min. Aliquots were analyzed for luciferase activity in a dual
luciferase reporter assay on a GloMaxTM 96 luminometer
(Promega, Madison, WI, USA) according to the manufacturer’s
instructions.Fig. 1. Schematic representation of human ABCC4 mRNA with locations of 30-UTR poly
begins at the start of the 30-UTR. Polymorphisms are shown as single lines throughout 
response elements are indicated with hatched areas and the speciﬁc miRNAs are noted. (B
30-UTR (239–273) are shown. Four nucleotides (CCUU) in ABCC4 30-UTR, which were m2.11. Statistical analysis
All miRNA transfection results were normalized to the values
obtained from samples transfected with negative miRNA. Statistical
analysis was performed using one-way ANOVA, followed by
Bonferroni correction. P < 0.05 was considered statistically signiﬁ-
cant. For microRNA and MRP4 correlations in human kidney samples,
MRP4 protein densitometric measurements were expressed relative
to the mean of all samples. microRNA expression data were natural
logarithm transformed to obtain a normal distribution. Pearson
correlation coefﬁcients were calculated and corresponding P
values < 0.05 were considered statistically signiﬁcant.
3. Results
3.1. miRNA predictions
Using web-based miRNA prediction tools eight miRNAs (hsa-
miR-26a, hsa-miR-26b, hsa-miR-124a, hsa-miR-143, hsa-miR-331-
3p, hsa-miR-506, hsa-miR-587 and hsa-miR-637) were predicted to
target the 30-UTR of ABCC4 mRNA. The location of these predicted
binding sites in the ABCC4 30-UTR is illustrated in Fig. 1.
3.2. Effect of predicted miRNAs on MRP4 expression
To investigate if predicted miRNAs had an effect on MRP4
expression, HEK293T/17 cells were transfected with 50 nM of
either negative control miRNA, siRNA against ABCC4 or predicted
miRNAs. siRNA against ABCC4 signiﬁcantly downregulated MRP4
protein in HEK293T/17 cells. Moreover, two out of eight tested
miRNAs, hsa-miR-124a and hsa-miR-506, signiﬁcantly down-
regulated MRP4 protein 20–30% (Fig. 2). miR-124a and miR-506
were further tested for concentration dependent effects. HEK293T/
17 cells were transfected with 5, 20, 50 or 100 nM of negative
control, miR-124a or miR-506. Both miRNAs tended to down-
regulate MRP4 protein in HEK293T/17 cells in a concentration
dependent manner (Fig. 3), although the trend did not reach
statistical signiﬁcance.morphisms and putative microRNA response elements (MRE). (A) The numbering
the ABCC4 30-UTR, with position and rs number indicated. The location of putative
) Sequences of miR-124a and miR-506 and their binding to a putative MRE in ABCC4
utated in functional experiments, are shown in bold.
Fig. 2. Effect of miRNA mimics on endogenous MRP4 expression in HEK293T/17
cells. Cells were transfected with 50 nM of negative miRNA, siRNA against ABCC4 or
predicted miRNA mimics. MRP4 protein expression was measured 72 h post
transfection. (A) A representative Western blot is shown. (B) Densitometry results
are from at least three independent experiments and are presented as mean ( S.D.).
MRP4 levels are expressed relative to GAPDH; negative miRNA is set at 100%. MRP4
expression in the presence of miRNA mimics was compared to negative miRNA by one-
way ANOVA, followed by Bonferroni correction; * P <0.05.
Fig. 3. Dose dependent downregulation of endogenous MRP4 in HEK293T/17 by
miR-124a and miR-506 mimics. Cells were transfected with 5, 20, 50 or 100 nM of
negative miRNA, miR-124a or miR-506. MRP4 protein expression was measured
72 h post transfection. (A) A representative Western blot is shown. (B)
Densitometry results are from at least three independent experiments and are
presented as mean ( S.D.). MRP4 levels are expressed relative to GAPDH; negative
miRNA is set at 100%. MRP4 expression at each concentration of miRNA mimic was
compared to the corresponding negative miRNA control by one-way ANOVA, followed
by Bonferroni correction but did not reach statistical signiﬁcance.
Fig. 4. Effect of siRNA, miR-124a and miR-506 on ABCC4 mRNA expression in
HEK293T/17 cells. Cells were transfected with 50 nM of negative miRNA, siRNA
against ABCC4, miR-124a and miR-506. ABCC4 mRNA expression was measured 24,
48 and 72 h post transfection by qRT-PCR. mRNA levels are expressed relative to
GAPDH levels. Results from one representative experiment (n = 3 independent
experiments) are presented as mean  S.D. (3 replicates/condition) with negative
miRNA set at 100%. Differences relative to negative miRNA were analyzed by one-way
ANOVA, followed by Bonferroni correction; * P <0.05.
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To investigate whether miRNA regulated MRP4 at the mRNA
level, ABCC4 mRNA levels were measured in HEK293T/17 cells 24,
48 and 72 h after transfection with 50 nM of either negative
control miRNA, siRNA against ABCC4, miR-124 or miR-506. siRNA
against ABCC4 signiﬁcantly reduced ABCC4 mRNA expression at all
of the tested time points while miRNAs only modestly reduced
ABCC4 mRNA expression (Fig. 4).
3.4. Effect of miR-124a and miR-506 on MRP4 function
To investigate whether the reduction in MRP4 protein
expression had corresponding effects on MRP4 function,
HEK293T/17 cells were transfected with 50 nM negative control
miRNA, siRNA against ABCC4, miR-124a or miR-506 and a
transport assay with monochlorobimane (MCB) was performed
72 h post transfection. MCB diffuses into cells and is metabolized
into the ﬂuorescent conjugate, bimane-glutathione, which is a
MRP4 substrate [36]. Efﬂux of bimane-glutathione was measured
to assess MRP4 function. Both miR-124a and miR-506 signiﬁcantly
reduced MRP4 transport activity almost 50% (Fig. 5). Interestingly,
the effect of siRNA on MRP4 function was very comparable to the
effects of miRNAs (Fig. 5), despite signiﬁcant differences in their
effects on MRP4 protein expression (Fig. 1).
3.5. Characterization of ABCC4 30-UTR haplotypes
The ABCC4 30-UTR region is highly polymorphic with a number
of SNPs in close linkage disequilibrium. The location of the 30-UTR
SNPs that were investigated is shown in Fig. 1. ABCC4 30-UTRhaplotypes were predicted in three ethnic groups (Caucasians,
African Americans and Asians) using HapMap and Pharmacoge-
nomics of Membrane Transporters (PMT) genotyping data. Six
haplotypes (H1-H6) were inferred with a frequency of more than
5% (Table 1); each haplotype contained at least two common
polymorphisms. H1 and H2 were present at a high frequency in all
three ethnic groups and can both be considered the reference
Fig. 5. Effect of siRNA, miR-124a and miR-506 on transport of bimane-glutathione by
MRP4. HEK293T/17 cells were transfected with 50 nM negative miRNA, siRNA, miR-
124a and miR-506. After 72 h, cells were incubated with monochlorobimane (MCB)
and bimane-glutathione efﬂux was measured. Bimane-glutathione ﬂuorescence was
normalized to total protein and results from one representative experiment (n = 3
independent experiments) are presented as mean  S.D. (4 replicates/condition).
Transport in cells transfected with negative miRNA is set to 100%. Differences between
the negative miRNA control and the miRNA mimics were analyzed by one-way ANOVA,
followed by Bonferroni correction: * P <0.05.
Fig. 6. Effect of miR-124a and miR-506 on relative luciferase activity of ABCC4 30-
UTR haplotypes. HEK293T/17 cells were transfected with pGL3 promoter empty
vector (EV) or plasmids containing ABCC4 30-UTR haplotypes (H1-H6) and Renilla
luciferase vector as a transfection control. Transfected cells were treated with
50 nM negative miRNA, miR-124a or miR-506 and results from one representative
experiment (n = 3 independent experiments) are presented as mean  S.D. (3
replicates/condition) relative to negative miRNA controls (set to 100%). Differences in
luciferase activity with the different treatments were analyzed by one-way ANOVA,
followed by Bonferroni correction; * P <0.05.
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Americans, while H4, H5 and H6 were African American speciﬁc.
3.6. Effect of ABCC4 haplotypes on miRNA regulation
A luciferase reporter gene assay was used to measure the
regulatory function of ABCC4 30-UTR haplotypes. Six ABCC4 30-UTR
haplotypes were ampliﬁed or created by site directed mutagenesis
and cloned into the pGL3-promoter vector downstream of
luciferase. Empty vector or an ABCC4 30-UTR haplotype luciferase
vector and a Renilla transfection control vector were co-transfected
with negative control miRNA, miR-124a or miR-506. Levels of
luciferase activity relative to Renilla activity were measured 24 h
post transfection. In the absence of miRNA mimics, ABCC4 30-UTR
haplotypes showed 0%–30% reduction in luciferase activity relative
to empty vector (Figs. 6 and 7), suggesting a dynamic effect of
endogenous miRNAs on the ABCC4 30-UTR. Addition of miR-124a
and miR-506 further reduced the luciferase activity of all six ABCC4
30-UTR haplotypes, to 35%–50% of empty vector (Fig. 6). None of
the polymorphisms/haplotypes reversed the inhibitory effect of
miR-124a and miR-506.
3.7. Speciﬁcity of ABCC4 regulation by miR-124a and miR-506
To further test the speciﬁcity of observed miRNA regulation of
the ABCC4 30-UTR putative binding site, sequences for miR-124aTable 1
ABCC4 30-UTR haplotypes and frequencies in three ethnic populations. ABCC4 30-UTR ha
software and HapMap and Pharmacogenomics of Membrane Transporters (PMT) genotyp
nucleotide differences and population frequencies for Caucasians (CA), African America
SNP 
rs3742106 rs4148551 rs4148553 rs9516521 rs1059751 PMT6316 rs95
T > G A > G G > A A > G T > C C > A A > 
H1 A C 
H2 G G 
H3 G G 
H4 G 
H5 G A 
H6 A C and miR-506 binding (located between base pairs 260–269 of
ABCC4 30-UTR) were mutated in H1 and H2 reporter plasmids
(Fig. 1). Empty vector, H1, H2, mutated H1 and mutated H2
luciferase reporter plasmids and Renilla transfection control vector
were co-transfected with negative control miRNA, miR-124a or
miR-506. Levels of luciferase activity relative to Renilla activity
were measured 24 h post transfection. miR-124a and miR-506 had
no effect on mutated plasmids (Fig. 7) conﬁrming speciﬁc binding
of these miRNAs to the ABCC4 30-UTR.
3.8. Correlation of MRP4 protein expression with miR-124a and miR-
506 levels in human kidney samples
To test in vivo regulation of ABCC4 by microRNAs, protein
and total RNA were extracted from 26 human kidney samples
and MRP4 protein and miR-124a and miR-506 levels were
measured. Expression of both miR-124a and miR-506 were
negatively correlated with MRP4 protein expression (Fig. 8).
This correlation was strongest for miR-124a expression and
MRP4 protein (Pearson’s correlation coefﬁcient 0.62,
P = 0.007). These results provide strong evidence for the
regulation of MRP4 expression by miR-124a, and to a lesser
extent miR-506, in human kidney.plotypes were inferred in Caucasians, African Americans and Asians using PHASE II
ing data. Six haplotypes (H1-H6) were inferred with a frequency of more than 5% and
ns (AA) and Asians (AS) are shown.
Haplotype
frequency
16520 rs9584273 rs16950472 rs9516519 rs34559063 CA AA AS
G G > A T > C A > C C >T
0.45 0.17 0.5
T 0.36 0.37 0.46
C 0.12 0.05 0
C 0 0.11 0
T 0 0.06 0
A 0 0.05 0
Fig. 7. Effect of disruption of putative binding site for miR-124a and miR-506 on
ABCC4 30-UTR function. HEK293T/17 cells were transfected with pGL3 promoter
empty vector (EV), plasmids containing ABCC4 30-UTR haplotypes 1 or 2 (H1 or H2)
or ABCC4 30-UTR haplotypes 1 or 2 mutated at their putative miR-124a/506 binding
site (H1-mut and H2-mut) and Renilla luciferase vector as transfection control.
Transfected cells were treated with 50 nM negative miRNA, miR-124a or miR-506
and results from one representative experiment (n = 3 independent experiments)
are presented as mean  S.D. (3 replicates/condition) relative to negative miRNA
controls (set to 100%). Differences in luciferase activity were analyzed by one-way
ANOVA, followed by Bonferroni correction; * P <0.05.
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The current study identiﬁed miR-124a and miR-506 as direct
negative regulators of ABCC4. Using available in silico tools, eight
miRNAs were predicted to bind ABCC4 30-UTR, but only miR-124a
and miR-506 were conﬁrmed to downregulate endogenous
expression and function of MRP4 protein in vitro. Reporter gene
assays conﬁrmed that miRNA targeting of ABCC4 30-UTR was
speciﬁc as disruption of their putative binding sites on ABCC4
resulted in rescue of the phenotype. Moreover, we observed a
negative correlation between miR-124 and miR-506 with MRP4
protein expression in human kidney, suggesting in vivo signiﬁ-
cance of our in vitro ﬁndings.
Over the past decade, knowledge of gene regulation by miRNAs
has rapidly evolved but there is still a very limited understanding
of miRNA regulation of genes involved in drug response [37].
Isolated reports on ABC transporters regulated by miRNAs indicate
a critical need for research in this area. ABCB1 (MDR1) expressionFig. 8. Correlation of miR-124a and miR-506 levels with MRP4 protein expression in hu
mean of RNU6B and RNU48) and MRP4 protein (relative to GAPDH) were correlated in 26
and microRNA data are natural logarithm transformed to obtain a normal distributi
correlations with corresponding P < 0.05 were considered signiﬁcant.is regulated by miR-27a and miR-451 [26] and by miR-200c [38].
ABCC1 (MRP1) expression is inversely correlated with miR-326
expression in a panel of advanced breast cancer tissues, suggesting
a role for this miRNA in MRP1 regulation [28]. Also, ABCC2 (MRP2)
expression is inversely correlated with miR-379 in cells treated
with rifampicin. miR-379 was conﬁrmed to bind the ABCC2 30-UTR
and reduce its expression [29]. ABCG2 (MXR) regulation by
miRNAs has been better studied and miR-328, miR-519c and miR-
520 h bind to ABCG2 30-UTR and reduce its expression
[30,32,39,40].
There is a recent report investigating regulation of a broad
range of ABC transporters in cancer tissues by miRNAs [34].
ABCA1 was regulated by miR-101 and miR-135b, ABCC1 by miR-
26a, miR-145, miR-199a, miR-199b and miR-296, ABCC5 by miR-
101, miR-125a, let-7a and let-7b, ABCC10 by let-7a and let-7b,
and ABCE1 by miR-26a, miR-135b and miR-145. ABCC4 regula-
tion was investigated in the same study and three miRNAs,
namely miR-125a, miR-125b and miR-143, were found to
downregulate ABCC4. Interestingly, in the current study miR-
143 was also predicted by in silico tools to bind ABCC4 mRNA 30-
UTR but failed to regulate endogenous MRP4 protein expression
in HEK293T/17 cells and was not investigated further. This
discrepancy could be explained by different experimental
systems used to test regulatory miRNAs. On the other hand,
the previous study did not identify miR-124a and miR-506 as
potential ABCC4 regulators. Liver tissue was used to identify
regulatory miRNAs, but miR-124a is predominantly expressed in
peripheral blood mononuclear cells, brain and kidney and miR-
506 is predominantly expressed in testicles, adrenal glands and
at low levels in kidney [41,42], and therefore these miRNAs were
not relevant in the previous study in liver.
Both miRNAs identiﬁed as ABCC4 regulatory elements in our
study share an almost identical seed sequence at the 50 end but
differ in their 30 ends (Fig. 1). miR-124a is repeatedly implicated in
neurogenesis [43] and in glioblastoma and leukemia biology
[44,45]. Interestingly, MRP4 was also implicated in leukemia
biology and shown to inﬂuence leukemic cell maturation through
regulation of intracellular cAMP levels [46]. There is also evidence
for MRP4 being upregulated in human leukemic cells resistant to 6-
mercaptopurine [47]. Previous data and our ﬁndings provide the
basis for more extensive investigation of cross talk between ABCC4
and miR-124a in normal blood cells and leukemia.
miR-506 was cloned relatively recently and is implicated in
cancer cell proliferation and growth [48,49]. There is also evidence
for up regulation of miR-506 in kidney allografts with ﬁbrosis [50].
Further studies are needed to elucidate potential cross talk
between ABCC4 and miR-506 in testicles and kidneys, where both
ABCC4 and miR-506 are expressed.man kidney samples. Levels of (A) miR-124 and (B) miR-506 (relative to geometric
 human kidney samples. MRP4 data are presented relative to the mean of all samples
on. Spearman correlation coefﬁcients were calculated for transformed data and
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were classiﬁed as a novel class of functional polymorphisms
present in the genome [51]. miRSNPs include SNPs affecting
miRNA biogenesis and SNPs in or near target miRNA binding sites.
The ABCC4 30-UTR is very polymorphic with several variants
present at a minor allele frequency close to 50%. Six major 30-UTR
haplotypes at a frequency greater than 5% were inferred with at
least two polymorphisms present in each haplotype. None of the
polymorphisms were located within or in proximity to the
predicted binding sites for miR-124a and miR-506 and had no
effect on the regulation of ABCC4 and MRP4 expression by these
miRNAs.
In conclusion, ABCC4 is directly regulated by miR-124a and
miR-506, polymorphisms in the ABCC4 30-UTR have no signiﬁcant
effect on this miRNA regulation and the expression of these
miRNAs is correlated with MRP4 levels in human kidney. Further
investigations are needed to elucidate the clinical signiﬁcance of
our ﬁndings and to characterize the regulation of ABCC4/MRP4
expression by miR-124a and miR-506 in additional tissues.
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